USA flag logo/image

An Official Website of the United States Government

Hip-Joint Resurfacing with Functional Human Cartilage

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2010 / STTR
Agency Tracking Number:
R42AR055414
Solicitation Year:
2010
Solicitation Topic Code:
NIAMS
Solicitation Number:
PA09-081
Small Business Information
CYTEX THERAPEUTICS INC.
2608 ERWIN ROAD DURHAM, NC 27715-1317
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2010
Title: Hip-Joint Resurfacing with Functional Human Cartilage
Agency: HHS
Contract: 2R42AR055414-02
Award Amount: $1,139,179.00
 

Abstract:

DESCRIPTION (provided by applicant): Degenerative joint disease accounts for substantial human suffering at tremendous social and economic cost. While prosthetic joint replacement is a well-established procedure, a finite life span makes this treatment unacceptable for younger or active individuals who often require progressively complicated revision surgeries. The goal of this Phase II STTR is to develop an osteochondral implant suitable for complete resurfacing of the osteoarthritic femoral head of the hip joint and proven ability to integrate with bone. The two novelties of this work are: (i) accelerated generation of an osteochondral implant within a brief period of in vitro culture and (ii) resurfacing of an entire joint instead of a focal defect. We will create a hemispherical layer of cartilage that replicates the load-bearing properties of the native tissue by combining adult human stem cells with a three- dimensionally woven scaffold in a new bioreactor. In vitro growth of the osteochondral implant will be quantified by histomolecular and biomechanical testing, and functional integration with vital bone will be assessed using a subcutaneous pouch model in an immunodeficient rodent. The combination of these emergent regenerative medical technologies isexpected to provide a novel means of developing functional, complex tissue engineered constructs that can resurface large segments of joints that have been affected by degenerative diseases such as osteoarthritis. PUBLIC HEALTH RELEVANCE: This project represents a Phase II STTR project to develop a novel tissue engineering approach to create osteochondral implants for joint resurfacing as a treatment for hip osteoarthritis. The technologic basis involves a combination of adult human mesenchymal stemcells grown on an anatomically shaped, three-dimensionally woven scaffold, which is cultured in a novel bioreactor system that can accelerate the generation of mechanically functional cartilage. The ultimate goal of this study is to develop a tissue engineering approach that can be used to resurface large segments of joints that have been affected by degenerative diseases such as osteoarthritis.

Principal Investigator:

Lisa E. Freed
617-452-2603
LFreed@draper.com

Business Contact:

Geoffrey R. Erickson
919-684-2521
cytex.therapeutics@gmail.com
Small Business Information at Submission:

CYTEX THERAPEUTICS INC.
2608 ERWIN ROAD DURHAM, NC -

EIN/Tax ID: 120524389
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
Charles Stark Draper Laboratory
555 Technology Square
CAMBRIDGE, MA 02139-
Contact: